Orthogonal IL-2 Receptor-Ligand Pair Engineering based Selective T Cell Targeting Service
Creative Biolabs' orthogonal IL-2 receptor-ligand pair engineering service is a specialized platform offering the custom design, synthesis, and rigorous validation of exclusive cytokine signaling systems. We provide proprietary engineered IL-2 ligands and matching receptor constructs that activate only your target T cell populations (e.g., CAR T or Tregs) with unparalleled specificity. Clients gain a potent, non-toxic tool for achieving robust in vivo T cell expansion, crucial for preclinical therapeutic development and advanced cell biology research.
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Introduction to Orthogonal IL-2 Targeting
Interleukin-2 (IL-2), fundamental to T cell proliferation via the JAK-STAT pathway, is constrained by intrinsic pleiotropy and associated cytotoxicity; its native receptor exhibits high affinity for IL-2, particularly in regulatory T cells. Orthogonal engineering creates a specialized lock-and-key mechanism through targeted mutagenesis of both the ligand and the receptor. This ensures the modified IL-2 ligand selectively engages the modified receptor, establishing a segregated signaling axis that circumvents the systemic toxicity of conventional IL-2 research modalities, thus positioning it as an indispensable component in sophisticated cell therapy research.
For an in-depth analysis of how our services can be tailored to your specific project needs, request a consultation.
Fig.1. Schematic of native IL-2R, orthogonal IL-2R, or γc family chimeric orthogonal receptor.
What We Can Offer
Customizable Receptor-Ligand Design
Tailor the IL-2 ligand and IL-2Rβ mutations in silico and ex vivo to precisely meet your specific affinity and T cell expansion requirements for any unique T cell research project.
Potency for ACT Scale-Up
Deliver the power to achieve up to an increase in engineered CAR T cell expansion in vivo, enabling lower dosing, reduced cost, and diminished reliance on harsh lymphodepletion in preclinical models.
Rigorous Gold-Standard Validation
Utilize comprehensive validation, including surface plasmon resonance (SPR) for kinetic proof and pSTAT5 functional screening to guarantee signal exclusivity and downstream signaling efficacy before delivery.
How Creative Biolabs Can Help
Why Choose Us?
|
Core Features
|
Key Advantages
|
|
Superior Selectivity
|
The utilization of this platform has demonstrably enhanced/facilitated the control of autoreactive T cell populations. Confirmation was obtained regarding zero cross-reactivity with native T cells, a critical endpoint that previous IL-2 mutein libraries failed to achieve.
|
|
Design Robustness for Future Translation
|
Demonstrated ability to enable an increase in CAR T cell expansion in vivo, with the capacity to rescue failing anti-leukemic responses in preclinical models.
|
|
Potency in ACT
|
The H9T approach mitigates the risk of severe VLS and other in vivo side effects associated with high-dose wt-IL-2, leading to potentially safer and more manageable in vivo study protocols.
|
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Customer Reviews
-
Superior Selectivity
The utilization of Creative Biolabs' service in our research has demonstrably enhanced the control of autoreactive T cell populations. We were able to confirm zero cross-reactivity with native T cells, a critical endpoint that previous IL-2 mutein libraries failed to achieve. - Dr. M***a R.
-
Potency & Expansion
The Creative Biolabs' service demonstrably facilitated the ex vivo expansion and maintenance of difficult-to-expand CAR T products. The consistent purity and potency of the delivered Orthogonal Ligand were excellent, enabling the efficient generation of research-grade material. - Dr. A***n K.
FAQs
Q: How does the orthogonal system compare with non-activating IL-2 muteins or IL-2/Antibody complexes?
A: Whereas conventional IL-2 muteins and complexes frequently exhibit detectable cross-reactivity and potential dose-limiting toxicities in preclinical models, our orthogonal system is predicated upon the complete ablation of native binding. This process introduces a novel binding pocket, thereby providing a biologically segregated signaling axis with confirmed specificity, which offers demonstrably superior control and research safety.
Q: What is the potential risk of the engineered IL-2 ligand accidentally activating native (wild-type) T cells in vivo?
A: A primary requirement of the engineering process involves the complete ablation of binding affinity between the orthogonal ligand and the native IL-2R subunits. Extensive in vitro validation, incorporating high-resolution SPR and functional pSTAT5 assays, substantiates that the final ligand candidates possess zero cross-reactivity with the wild-type receptor, ensuring a high margin of research safety.
Related Services
Cytokine enhanced ACT Development
A comprehensive service integrating orthogonal IL-2 systems with customized cytokine strategies to maximize engineered T cell persistence, anti-tumor function, and homing capabilities for the most advanced ACT research projects.
Learn More →
IL-2 Variant H9T enhanced T Cell Engineering
Specialized service for the rational design and synthesis of highly potent, second-generation IL-2 muteins focused on optimizing receptor binding kinetics for specific T cell subset expansion without utilizing the full orthogonal system.
Learn More →
How to Contact Us
Creative Biolabs is committed to delivering pioneering research solutions, establishing new standards for T cell therapeutic precision and security. We invite collaboration to translate innovative therapeutic concepts into a robust and rigorously controlled preclinical reality. Please contact us.
For Research Use Only | Not For Clinical Use
